Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Profit After Tax (2016 - 2025)

Amicus Therapeutics' Profit After Tax history spans 16 years, with the latest figure at $1.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 88.53% year-over-year to $1.7 million, compared with a TTM value of -$27.1 million through Dec 2025, up 51.68%, and an annual FY2025 reading of -$27.1 million, up 51.68% over the prior year.
  • Profit After Tax for Q4 2025 was $1.7 million at Amicus Therapeutics, down from $17.3 million in the prior quarter.
  • The five-year high for Profit After Tax was $17.3 million in Q3 2025, with the low at -$85.3 million in Q1 2022.
  • Average Profit After Tax over 5 years is -$36.1 million, with a median of -$38.5 million recorded in 2023.
  • Biggest YoY gain for Profit After Tax was 357.19% in 2025; the steepest drop was 88.53% in 2025.
  • Tracing FOLD's Profit After Tax over 5 years: stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then crashed by 88.53% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Profit After Tax are $1.7 million (Q4 2025), $17.3 million (Q3 2025), and -$24.4 million (Q2 2025).